And think about inflammatory bowel disease and the impact of Stelara and Tremfya and the potential ... A few initial considerations outlined on this chart regarding the planned acquisition of ...

Surveying the next 12 months, J&J expects to chart roughly ... IL-23 inhibitor Skyrizi. As with Skyrizi and Humira, Tremfya has gradually been adopting indications held by Stelara, such as psoriat ...

Stelara, used to treat plaque psoriasis ... The drug is used to treat a form of blood cancer known as myeloma. AbbVie’s (ABBV) Skyrizi generated $11.7 billion in sales in 2024 — about 20% ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

J&J has phase 2 results in hand with Tremfya in Crohn's, but Lilly's mirikizumab is closest behind Skyrizi, with results of a head-to-head trial pitting the antibody against Stelara due later this ...

reached clinical remission after 6 months on risankizumab (Skyrizi) versus ustekinumab (Stelara), according to a head-to-head trial. In the phase III study, 59% of patients (n=255) receiving ...

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

Whether you’re after specific iPhone dimensions or want an iPhone screen size comparison chart to help visualize your options, we’ve got you covered. Let’s compare iPhone sizes to help you find the ...